Clinical data collected from researches showed that anti-TRIM21 antibodies are one of the independent serological risk factors for different subtypes of IIM-ILD, with a positivity rate of up to 50%, which is similar to the frequency of anti-Jo-1 in IIM-ILD and are associated with the severity and prognosis of IIM-ILD, Table 4 (159, 161, 162, 164, 165, 168, 169). This evidence concerns the gene TRIM21 and interstitial lung disease.